Skip to main content
OpenTrials
Completed

NCT Number: NCT00396136

COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring

The objective of this post approval registry is to confirm the long-term safety and effectiveness of the Corox Over-the-wire (OTW) Steroid Left Ventricular (LV) lead as used in conjunction with a BIOTRONK cardiac resynchronization therapy defibrillator (CRT-D). The Corox OTW Steroid LV Lead is capable of providing permanent pacing therapy to the left ventricle in a CRT-D system. The following are the specific objectives to be evaluated during this post-approval registry:

* Long-term effectiveness of the COROX OTW Steroid in providing biventricular pacing * Safety of the COROX OTW Steroid LV pacing lead

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Biotronik

Lake Oswego, Oregon, 97035, United States

About this study

This post approval registry enrolled 221 patients from 34 centers. The collection of registry data continued for three years for each enrolled subject. Potential patients were screened by the enrolling physician according to the detailed inclusion and exclusion criteria below.

The specific required visits for this registry are: Enrollment, Three-month, Six month, One-year, Routine Follow-Ups (every subsequent 6 months), Interim follow-ups for Corox OTW Steroid LV lead related visits, and Out of Service visit. Data will be collected at each patient follow-up. The programmed pacing parameters, LV pacing impedance, and LV pacing threshold measurement at 0.5ms pulse width will be obtained. The programming parameters will be set to best suit each patient. If adequate system function, including effective CRT, cannot be obtained, the patient should not be selected for the registry.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Successfully implanted BIOTRONIK CRT-D system, including the Corox OTW Steroid LV Lead, from 1-30 days prior to enrollment
  • Able to understand the nature of the registry and give informed consent
  • Available for follow-up visits on a regular basis at the investigational site
  • Age greater than or equal to 18 years

Exclusion criteria

  • Enrolled in another cardiovascular or pharmacological clinical investigation
  • Planned cardiac surgical procedures or interventional measures within the next 6 months
  • Expected to receive a heart transplant within 6 months
  • Life expectancy less than 6 months
  • Presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Pregnancy

Treatment and study plan

Corox OTW Steroid Left Ventricular Lead

Device

This is a registry: no study required interventions necessary.

Primary outcomes

  1. Long-term Effectiveness of the COROX Over-the-wire (OTW) Steroid in Providing Biventricular Pacing

    Time frame: All follow-ups for 3 years post implant

    Evaluate threshold voltage of the COROX OTW Unipolar Lead.

  2. Safety of the COROX OTW Steroid LV Pacing Lead

    Time frame: 3 years post implant

    Number of participants with LV lead related adverse events requiring additional invasive intervention to resolve.

Sponsors and collaborators

Lead sponsor

Biotronik, Inc.

Industry

Registry information

Official study title

Corox OTW Steroid LV Lead Monitoring

Important dates

Study start
2006
Primary completion
2011
Study completion
2011
First posted
Nov 6, 2006
Registry last updated
May 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.